BAM
BLUE

Belpointe Asset Management’s bluebird bio BLUE Stock Holding History

Belpointe Asset Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-58
Closed -$110K – 506
2018
Q3 		$110K Buy
+58
New +$120K 0.02% 621

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belpointe Asset Management's BLUE Position: Q4 2018 in Review

Belpointe Asset Management sold out of bluebird bio (BLUE) in Q4 2018, closing a stake of 58 shares — an estimated $110K sold.

Belpointe Asset Management first reported a position in BLUE in Q3 2018 and held it in 1 quarter. The position peaked at $110K in Q3 2018. 251 funds tracked by Wall St. Rank hold BLUE as of Q4 2018.

  • Belpointe Asset Management reported no remaining bluebird bio position as of Q4 2018 after selling out during the quarter.
  • Belpointe Asset Management sold 58 bluebird bio shares in Q4 2018, an estimated $110K.
  • Belpointe Asset Management first reported a position in bluebird bio in Q3 2018 and held it in 1 quarter.
  • Belpointe Asset Management's bluebird bio position peaked at $110K in Q3 2018.
  • 251 funds tracked by Wall St. Rank held bluebird bio as of Q4 2018.

Based on Belpointe Asset Management's 13F filing for Q4 2018, filed 6 Mar 2019.